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Retinoic acid (RA), a metabolite of retinol, is one of the most biologically active forms of retinoid and 
plays vital roles in embryonic development and in the regulation of cell proliferation and differentiation. 
Knowing that liposomes simulate cell membranes and that hydrogel is an ideal delivery vehicle for topical 
medicine, liposome-hydrogel is a novel preparation that has synergistic advantages over each component 
separately. Our objective was to investigate the characteristics of RA liposome-hydrogel. For quality 
control of the RA-loaded liposomes, we measured their morphology, particle size, Zeta-potential, and 
entrapment efficiency. Then we determined the viscosity of RA liposome-hydrogel. Next, the diffusion 
through mouse skin was explored, followed by investigation of the mRNA expression levels of Ker18, 
REX1, and α-FP using Q-PCR. The results showed that RA liposome-hydrogel penetrates the mouse 
skin effectively. The permeation rates were: Qn (%) of RA liposome-hydrogel < Qn (%) of RA-loaded 
liposome < Qn (%) of RA. The mRNA expression levels were dose-dependent and the effective dose 
decreased between vehicles due to their different release rates. F9 mouse teratocarcinoma stem cells 
were an ideal model to explore the mechanism of RA liposome-hydrogel in stem cell differentiation.
Uniterms: Retinoic acid (RA). RA liposome-hydrogel/characteristics. RA liposome-hydrogel/preparation. 
RA liposome-hydrogel/diffusion/experimental study. F9 cell/differentiation.
O ácido retinóico (RA) é um metabolito de retinol. Ele também é uma das formas mais biologicamente 
ativas de retinóide. Desempenha papel vital no desenvolvimento embrionário e na regulação da 
proliferação e diferenciação celular. Sabendo-se que lipossomas simulam a membrana das células e que 
hidrogel é um sistema ideal para o medicamento tópico, o lipossoma-hidrogel é uma nova preparação, 
que apresenta vantagens sinérgicas em relação a cada um dos componentes separados. Nosso objetivo 
foi investigar as características de RA lipossoma-hidrogel. A fim de controlar a qualidade do lipossoma 
carregado com RA, medimos morfologia, tamanho das partículas, potencial zeta e eficiência de retenção. 
Em seguida, determinou-se a viscosidade de RA lipossoma-hidrogel. Em seguida, avaliou-se a sua 
difusão através da pele de camundongos, seguida da investigação dos níveis da expressão de mRNA 
de Ker18, REX e de α-FP, utilizando-se Q-PCR. Os resultados mostraram que RA lipossoma-hidrogel 
pode penetrar na pele do camundongo de forma eficaz. As taxas de permeação foram: Qn (%) de RA 
lipossoma-hidrogel<Qn(%) de lipossoma RA- carregado <Qn (%) de RA. Os níveis de expressão de 
mRNA foram dependentes de dose e a dose efetiva diminuiu entre os veículos devido às diferentes taxas 
de liberação, As células estaminais de teratocarcinoma F9 de camundongo mostraram-se como modelo 
ideal para explorar o mecanismo de diferenciaçãode células tronco pelo RA lipossoma-hidrogel.
Unitermos: Ácido retinóico (RA). RA lipossoma-hidrogel/características. RA lipossoma-hidrogel/
preparação. RA lipossoma-hidrogel/difusão/estudo experimental. Células F9/diferenciação.
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INTRODUCTION
Liposome-hydrogel is a combination of two organic 
formulations - liposome and hydrogel. The liposomal 
delivery system is composed of biomaterials such as 
soybean phospholipid, lecithin, cephalin, and cholesterol. 
It can form phospholipid bilayer membranes through 
self-assembly. It is a biomaterial preparation often 
selected as a good model of bio-membrane simulation 
(Fujisawa, Atsumi, Kadoma, 1989) It can penetrate body 
barriers such as the blood–brain barrier (Aviral et al., 
2009), gastric mucous membrane (Fricker et al., 2010), 
intestinal mucous membrane (Goto et al., 2006), and cell 
membrane (Hossain et al., 2006). It can target special cells 
including cancer cells (Gabizon, Shmeeda, Barenholz, 
2003) and brain cells (Dodu, Rotari, Vazques, 2012). Then 
it accumulates the drugs in the target region to reach and 
maintain the effective concentration by slow release of 
drugs from the liposomes. So it is also regarded as a slow-
release preparation. Drugs such as shikonin enveloped 
into liposomes could be released slowly (Xia et al., 2013).
Liposomes in the nanometer size range can penetrate 
small capillaries and be taken up by the cells, thereby 
allowing an efficient drug accumulation in the target 
tissues and sustained drug release over a period of days 
or even weeks after administration. In addition, the 
sterical stabilization by incorporation of polyethylene 
glycol (PEG) into the bilayer membranes mediated long 
circulation half-lives of about 16 h in mice or rats, and 24 h 
or longer in humans after i.v. administration (Allen, 1994). 
All of the above-mentioned liposomes could be used as 
controlled delivery systems (Mumper, Hoffman, 2000).
Hydrogel is an ideal delivery vehicle for topical 
medicine. It forms a macromolecular network system, 
with uniform drug dispersal and adheres closely to skin or 
mucous membrane, using hydration and interaction. It is 
beneficial for topical drugs release and constitutes a novel 
preparation for drug administration to skin, eye mucosa, 
nasal cavity, and other locations, as seen in studies such 
as ciprofloxacin hydrochloride release from poloxamer-
based ocular hydrogel formulations (Mansour et al., 2008), 
paeonol and ondansetron nasal gel adhesion and thermal 
stability (Bhalerao et al., 2009; Chen et al., 2009), and 
penetration through mouse skin and the associated release 
kinetics (Panigrahi et al., 2006).
Liposome-hydrogel systems can offer synergistic 
advantages such as increasing the drug affinity of the 
mucous membrane of the skin, eyes, gastrointestinal tract, 
and other areas. The drug bioavailability in the liposome-
hydrogel system would be improved. Therefore, in this 
study we applied the liposome-hydrogel system to deliver 
anti-cancer drugs to penetrate cancer cells.
RA is a member of the most biologically active 
forms of retinoid. It is an anti-cancer drug that induces 
cell differentiation and suppresses cell growth in a wide 
spectrum of cancer cell lines. The mechanisms of anti-
cancer effects underlying RA appear to be associated with 
its ability to modulate cell differentiation, growth, and 
apoptosis, thereby preventing angiogenesis. (Vivaldi et 
al., 2009). These actions are mediated by nuclear retinoid 
receptors (RARs). RARs are expressed in F9 mouse 
teratocarcinoma stem cells. The RA response is mediated 
by two families of nuclear receptors that function as 
ligand-dependent RAR transcription activators (Laudet, 
Gronemeyer, 2002). RARs regulate specific subsets of 
target genes during RA-induced differentiation of F9 
mouse teratocarcinoma stem cells (Dan, Gudas, 2008).
However, oral treatment with RA is associated with 
a progressive decrease in plasma concentrations over time, 
leading to relapse of the disease and retinoid resistance 
(Muindi et al., 1992) because the lower drug concentrations 
are no longer able to sustain the differentiation effects on 
the cancer cells in vivo. To maintain the biological activity 
of RA, liposome-hydrogels might be a good choice. The 
RA liposome-hydrogel is a biocompatible drug carrier. As 
is the case for many other toxic drugs, encapsulation of 
RA in the liposome-hydrogel has been shown to decrease 
its toxic effects, sequester RA at target locations, and 
amplify its therapeutic effect (Weinstein, Leserman, 1984). 
RA incorporated in the liposome-hydrogel has reduced 
in vitro toxicity and retained its full biological activity 
(Parthasarathy et al., 1994). Furthermore, the liposome-
hydrogel may protect RA from the catabolic enzymes of 
the target cells, thus exposing the target cells to the active 
form of RA for longer periods (Parthasarathy, Mehta. 
1998).
F9 mouse teratocarcinoma stem cells belong to 
the family of embryonic carcinoma stem cells. They 
resemble the pluripotent mass cells of mouse blastocysts. 
Possessing many properties of embryonic stem (ES) cells, 
F9 cells can differentiate into primitive endoderm cells in 
monolayer cultures or into proximal (visceral) endoderm 
cells in the aggregation culture when they contact RA. 
Therefore, the mouse F9 cell is a perfect model system 
to investigate the mechanism of RA liposome-hydrogel 
in cell differentiation and cell growth control, and in the 
biochemical basis of early embryonic development (Jiao, 
Li, Chiu, 2012).
Currently no paper has reported about retinoic acid 
(RA) liposome-hydrogel. Therefore, it is valuable to 
investigate RA liposome-hydrogel thoroughly for wide 
future application.
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MATERIAL AND METHODS
Material
RA was bought from Sigma (St Louis, MO, USA). 
Soybean phospholipid and cholesterol were purchased 
from the Sinopharm Chemical Reagent Co. Ltd., 
China. Carbomer 940 was purchased from the Saipu 
Macromolecule Material Co. Ltd., China. Dulbecco’s 
Modified Eagle’s Medium (DMEM), α-Minimum 
Essential Mediumα (α-MEM), Ham’s F12 medium, and 
Fetal Bovine Serum (FBS) were bought from the GIBCO 
Co. All other chemicals and solvents were of analytical 
reagent grade.
Cell culture
Undifferentiated F9 mouse teratocarcinoma 
stem cells (ATCC, USA) were cultured in the α-MEM 
containing 10% FBS, 1 mM glutamine and antibiotics 
(100 mg streptomycin/mL and 100 U of penicillin/mL).
For the experiments involving cell differentiation 
into visceral endoderm, F9 mouse teratocarcinoma stem 
cells were seeded at 1×106 cells/190mm bacteriological 
petri dish maintained in a 1:1 mixture of DMEM and 
Ham’s F12 medium supplemented with 10% FBS, 1 mM 
glutamine, and antibiotics (100 mg streptomycin/mL 
and 100 U of penicillin/mL). The cells were cultured in 
the presence of 50 nM RA, RA-loaded liposome, or RA 
liposome-hydrogel for seven days. The morphological and 
gene expression changes were investigated.
Preparation of RA liposome-hydrogel (RA-L-G)
RA-loaded liposomes (RA-L)
RA-L was prepared according to the procedure 
described in our previous reports (Xia et al., 2013). 3 mg 
RA, 100 mg soybean phospholipid, and 20 mg cholesterol 
were dissolved in 10 mL dehydrated alcohol. The mixture 
was aspirated using a syringe and injected into 10 mL 
phosphate-buffered saline (PBS, 8 g NaCl, 0.2 g KCl, 1.44 
g Na2HPO4, and 0.24 g KH2PO4 dissolved in 1 L distilled 
water, pH7.4) (60 ± 5°C). The final concentration of RA-L 
was 1mM. Blank control samples were prepared using the 
same method without RA. After vaporizing the alcohol, 
the solution was filtrated using a membrane (pore size of 
0.22 μm).
RA liposome-hydrogel (RA-L-G)
RA-L-G was prepared by dissolving 1.0 g carbomer 
940 powder in 100 mL phosphate-buffered saline 
containing RA-L. The solvent was allowed to swell at 
room temperature overnight. Then we added 10% NaOH 
and adjusted the pH of the solvent to about 7.0 to allow 
formation of the transparent hydrogel.
Particle size and Zeta-potential measurement
The RA liposomal formulation was diluted with PBS 
and put into the sample cells of the Zeta potentiometer 
(Brookhaven instrument corporation) to measure the 
particle size and Zeta-potential and ultimately to analyze 
the formulation using the ZetaPlus particle sizing software. 
All measurements were performed immediately after 
liposome preparation.
Entrapment efficiency determination using the 
traditional dialysis method
Solutions with different concentrations of RA 
(0.3, 0.6, 0.9, 1.2, 1.5, and 1.8 µM) were prepared in 
dehydrated alcohol. The absorbance of each solution 
was determined by UV/Vis spectrophotometry (DU730, 
Beckman, America) at the characteristic wavelength of 
RA (347 nm). The calibration curve of RA (A = 0.5017C 
+ 0.0321 (r = 0.9999)) was followed. The detection limit 
of RA was 0.3µM. The degree of precision was excellent 
(RSD=1.02%). The RA solutions were stable for two hours 
(RSD=0.85%).
The entrapment efficiency of RA-L was estimated 
according to the calibration curve. 1 mL of each liposomal 
suspension in PBS was suspended in 10 mL dehydrated 
alcohol, followed by vigorous spinning for 10 min, 
to destroy the liposome structure, releasing RA into 
the organic phase. Absorbance of the organic phase 
was measured and the total amount of RA (Qtotal) was 
calculated. Another 1 mL of each liposomal suspension 
in PBS was dialyzed adequately and the amount of RA 
that was not incorporated into the liposomes (Qout) was 
calculated. Then the entrapment efficiency was calculated 
according to the following equation:
Entrapment Efficiency (%) = (Qtotal - Qout )/ Qtotal ×100
Viscosity determination
We studied the rheological behavior of our 
manufactured RA-L-G by alteration of shear rate. A 
rotating cylinder viscometer (NDJ-8S, China) was used. 
The viscosity of the hydrogel was measured under room 
temperature, at shear rates of about 60.0 r / min with rotor 
2#.
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Passage through the mouse skin in vitro
Built mouse skin membrane in vitro
The mouse (ICR, 20 ± 2 g) was anesthetized by 
injection of 20% urethane solution into the peritoneal 
cavity (0.1 mL/10 g). The mouse skin was carefully 
shaved and then removed. The blood vessels could be 
observed clearly. The separated mouse skin membrane 
was thoroughly washed in isotonic PBS (pH 7.4) and 
used at once.
All experimental procedures were approved 
by the Institutional Animal Care and complied with 
the requirements of the National Acts on the use of 
experimental animals (People’s Republic of China).
The permeate studies of RA, RA-L and RA-L-G
The studies of RA, RA-L, and RA-L-G permeation 
through the mouse subcutaneous mucous were conducted 
in a Franz-type diffusion cell at 37°C with a diffusional 
area of 1.12 cm2. First, PBS buffer (pH 7.4) was added 
into the receiver chamber (25.5mL). Teflon-coated 
magnetic beads were used in the receiver chamber to stir 
continuously. The mouse skin membrane was clamp-
mounted between the donor and receiver chambers of 
the diffusion cell. Before the start of the experiment, the 
membrane was equilibrated for 1 h with PBS buffer (pH 
7.4) at 37 °C. For the permeation study, 1 mL of RA, 
PA-L, and RA-L-G were added into the donor chamber 
of the diffusion cell, in close contact with the mouse skin 
membrane. The permeation experiments were performed 
for 2880 min. 100 µL samples were taken from the receiver 
chambers. The amount of RA permeated was determined at 
time intervals of 30, 60, 120, 180, 240, 300, 360, 540, 720, 
1440, 2160 and 2880 min by UV/Vis spectrophotometry 
(DU730, Beckman, America). The permeability rate was 
then determined.
RA-L-G regulated the expression level of Ker18, 
REX1, α-FP
The mRNA isolation and cDNA synthesis
Total cellular mRNA was extracted from untreated 
F9 cells (control) or treated F9 cells with RA, RA-L, or 
RA-L-G according to the TRIZOL protocol. The quality 
of the mRNA was tested in 2.0% agarose gel stained with 
ethidium bromide (EB). The mRNA concentration was 
measured using a spectrophotometer.
For first strand cDNA synthesis, 1μg total RNA was 
used according to the protocol of the M-MLV reverse 
transcriptase (Reverse Transcription System, Promega 
Co.): (1) We added 1 µg total mRNA, 1 µL Oligo(dT)15 
Primer, and 17 µL DEPC H2O to the PCR tubes, which 
were held at 70 °C for 5 min. Then we took the tubes out 
immediately and put them onto ice for 5 min. (2) We built 
the 25 µL reaction solution using the mixed solution above 
plus 5 µL 5×Reverse Transcription Buffer, 1.25 µL 10 mM 
dNTP Mixture, 0.75 µL RNase Inhibitor (40 U/µL), and 
1 µL M-MLV Reverse Transcriptase, 25 U/µL). (3) We 
put the 25 µL reaction solution into the PCR instrument 
at 42 °C for 60 min, then at 70°C for 15 min. (4) The first 
strand cDNA was synthesized and stored at -20 °C.
Q-PCR
After reverse-transcription (RT), the quantitative 
polymerase chain reaction (Q-PCR) was performed with 
our primary RT reaction product cDNA to determine 
Ker18, REX1, and α-FP gene expression. All actions were 
carried out in translucent, flat-bottom, 96-well plates. 
It was a 20µL PCR action system. cDNA was diluted 
12 times and we took out 4 µL as the template. Then 
3 µL upstream primer, 3 µL downstream primer, and 
10 µL SYBR® Green Real-time PCR Master Mix (No. 
QPK-201, Toybo Co., Ltd., Osaka, Japan) were mixed. 
Q-PCR amplification was initiated in a 7300 real-time 
PCR instrument (ABI Co.) with 10 min of denaturation at 
95 °C followed by 40 cycles at 95 °C for 15 sec, 60 °C for 
1 min. Three parallel reactions were done for each sample.
The primer sequences for Ker18: Sense: 5′-AGA TGG 
AGC AGC TCA ATG-3′
Antisense: 5′-GTT TGC ATG GAG TTG CTG-3′
The primer sequences for REX1: Sense: 5′-ATG GAC 
TAA GAG CTG GG-3′
Antisense: 5′-CTT GAA CAA TGC CTA TGA CT-3′
The primer sequences for α-FP: Sense: 5′-ACC TCA GCA 
GAG CTG ATC GA-3′
Antisense: 5′-TTG CAG CAG TGG CTG ATA CCA -3′
The primer sequences for β-actin: Sense: 5′- GTGGGG-
CGCCCCAGGCACCA-3′
Antisense: 5′- CTCCTTAATGTCACGCACGATTTC-3′
Specificity was determined for each reaction 
from the dissociation curve of the PCR product. This 
dissociation curve was obtained by following the SYBR 
Green fluorescence level during gradual heating of the 
PCR products from 60°C to 95 °C.
Relative quantification of each gene expression level 
was normalized according to β-actin gene expression. 
Relative mRNA expression was generated using the 
2 − ΔCT method. First, the transcription level of the 
specific gene in different samples was normalized using 
the formula ΔCt (specific gene) = Ct (specific gene) – 
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Ct (β-actin). We chose the minimum value of ΔCt as 
the standard. Finally, we calculated the relative mRNA 
according to the formula of 100×2 –[ Δ Ct (specific gene) – Δ Ct (specific 
gene) the lowest level]. 
Statistical analysis
All values were expressed as mean ± SD. Differences 
in the treatments were expressed as means and compared 
statistically using least significant differences (LSD) at 




We observed the bigger segments, visible through 
the microscope and obtained before filtration using the 
Φ 0.22μm membrane. RA-L was identified by its double 
phospholipid membrane. Retinoic acid is almost insoluble 
in water and it is supposed to be intercalated into the 
lipid bilayer (Figure 1). They simulated the cellular 
phospholipid membrane.
Particle size, Zeta-potential, entrapment 
efficiency and viscosity
The particle size of RA-L was 137.9 ± 16.1 nm. 
The Zeta-potential of the particles was -32.54 ± 4.64 mV. 
The entrapment efficiency of RA-L was 79.81 ± 9.63% 
determined by the traditional method of dialysis. The 
viscosity of RA-L-G was 7.25 ± 1.23 Pa·s.
The permeation rate of RA, RA-L, RA-L-G in vitro
The cumulative permeation rate Qn (%) was 
calculated according to the following equation:











where CnVn was the quantity of RA in the receiver 
chamber; C iVi was the quantity of RA removed for 
determination; and CRA/RA-L/RA-L-G VRA/RA-L/RA-L-G was the total 
quantity of RA, RA-L, or RA-L-G in the donor chamber. 
Qn (%) of RA, RA-L, and RA-L-G in vitro at 2880 min 
were 50.25 ± 5.75%, 22.56 ± 3.42%, and 12.59 ± 2.83% 
(Figure 2). The results at 2880 min showed Qn (%) between 
RA and RA-L; RA and RA-L-G had statistical significant 
difference (P<0.01**); Qn (%, 2880 min) between RA-L 
and RA-L-G had significant difference.
Qn (%) of RA-L-G was lower than that of RA-L 
and RA. Qn (%) of RA-L-G, RA-L and RA increased 
progressively, indicating that the liposome-hydrogel 
could release RA slowly. Therefore, liposome-hydrogel 
improved RA bioavailability because of its slow and 
controlled release, suggesting a valuable clinical 
application in anti-cancer treatment.
Differentiation of F9 mouse embryonal 
teratocarcinoma stem cells
Using standard methods for inducing F9 cell 
differentiation, the cells were grown in suspension in 
bacteriological Petri dishes in medium containing 50nM 
FIGURE 1 - RA-L with its double phospholipid membrane. A. 
The double phospholipid membrane was observed through the 
microscope (400x). B. The schematic diagram of the liposomes. 
Retinoic acid is almost insoluble in water and it is supposed to 
be intercalated into the lipid bilayer
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RA as shown in Figure 3. The cells aggregated to form 
embryonic bodies with a ring of outer cells that resembled 
visceral endoderm cells. After induction of F9 cell 
differentiation with RA, RA-L, and RA-L-G for a period 
of time, these outer layers of the embryonic bodies became 
rough, while the F9 cell aggregate grown in suspension 
under the same condition without RA treatment had a 
smooth surface. This morphologic change of F9 cell 
aggregates indicated that RA, RA-L, and RA-L-G induced 
F9 cell differentiation.
The expression level of α-AFP, Ker18, and REX1 in 
F9 mouse embryonal teratocarcinoma stem cells 
with RA, RA-L, and RA-L-G treatment
To fur ther  descr ibe  F9 mouse  embryonal 
teratocarcinoma stem cells, we detected the mRNA 
expression of Ker18, REX1, and α-AFP by Q-PCR after 
seven days of treatment with RA, RA-L, and RA-L-G. 
The dose-dependent results are shown in Figure 4. The 
effective dose decreased progressively (RA> RA-L> 
RA-L-G) because of their different release rate.
DISCUSSION
RA is a biologically active molecule related to 
vitamin A. It is one of the endogenous compounds that 
mainly controls the growth and differentiation of some 
special tissues. Specifically, RA has an effect on the growth 
and differentiation of malignant cells. It has been used for 
the chemoprevention and chemotherapy of various types 
of cancer, such as promyelocytic leukemia (Meng-er et al., 
1988), acute cervical cancer (Lippman et al., 1992), and 
metastatic squamous cell cancers of the skin (Lippman 
et al., 1992), as well as in breast, lung, head, neck, renal, 
and prostate cells (Sun, Lotan, 2002). It has evoked our 
interests in exploring RA as a therapeutic agent for cancer 
treatment.
RA induces F9 mouse teratocarcinoma stem cells 
to differentiate into primitive endoderms and further 
into visceral and parietal endoderms, depending on the 
culture conditions. Primitive and visceral endoderms 
show epithelium-like properties during mammalian 
development. RA up-regulates the expression of 
differentiation markers for primitive, visceral, and 
parietal endoderm in F9 cells (Inoue et al., 2009). 
F9 mouse teratocarcinoma stem cells increase the 
expression of Ker18 in response to RA to differentiate 
into primitive endoderm. The mRNA levels of Rex1 are 
high in F9 stem cells and reduced during RA-induced 
differentiation (Hosler et al., 1989). Thus, Rex1 is a marker 
of undifferentiated F9 mouse teratocarcinoma stem cells. 
Further differentiation of F9 mouse teratocarcinoma 
stem cells occurs along two pathways depending on the 
FIGURE 2 - The permeation curves of RA, RA-L, and RA-L-G.
FIGURE 4 - The effect of RA, RA-L, and RA-L-G on the mRNA 
expression of Ker18, REX1, and α-AFP in F9 mouse embryonal 
teratocarcinoma stem cells.
FIGURE 3 - Induction of F9 cell differentiation with RA, RA-
L, and RA-L-G for seven days. A is the control, B is RA, C is 
RA-L, and D is RA-L-G.
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culture conditions. After forming aggregates, the cells 
can differentiate into visceral endoderm, as indicated by 
the expression of a unique marker, α-fetoprotein (α-FP) 
(Young, Tilghman, 1984). So Ker18, Rex1, and α-FP 
were chosen as the important indicators to investigate 
RA-induced cell differentiation.
Liposomes have bi layer  l ip id  membranes 
that resemble cell membranes. It is well known that 
phospholipids composing most biological membranes 
are in their liquid-crystalline state under physiological 
conditions and this plays a major role in the control of 
membrane-mediated functions (Jemiola-Rzeminska 
et al., 2005). Moreover, liposomes have some special 
important properties. They can be nontoxic, long-lasting, 
slow-release, biocompatible with drugs, and inert toward 
many drugs. Additionally, they can decrease the toxicity of 
drugs, target lymph tissue, and increase the solubility and 
stability of drugs (Coimbra et al., 2011). Such properties 
make liposomes a suitable biomaterial for controlled drug 
release systems.
Indeed, to comply with the rapidly increasing 
demands in medical treatment and health care, various 
kinds of liposomes have been made and tested so far. Based 
on recent progress in organic synthesis techniques, these 
liposomes could target special tissue exactly, including 
brain, cancer, and others. For example, to improve the 
targeting on specific tumors, methods for modifying the 
surface of liposomes with anti-smooth-muscle cell actin 
(Laing et al., 2010), antibody anti-EGFR antibodies (Kim 
et al., 2009), and anti-VEGF antibody (Tirand et al., 2006), 
as well as folate (Zhang et al., 2004), have been adopted 
in the experiments.
When the liposomes were put into the hydrogel, they 
formed liposome-hydrogel, with novel characteristics and 
advantages. How does the liposome-hydrogel interact with 
the target cells? Once the liposome-hydrogel contacts the 
cells, the liposome might first diffuse and escape from the 
networks of the hydrogel. Then the liposome membrane 
might fuse with that of the cells. The drug would release 
from the liposomes across the membrane into the target 
cells. Wong et al. (2007) tried to investigate and analyze 
the moment of membrane fusion using urchins and eggs. 
The behavior of the liposomes with the membranes of cells 
such as cancer cells is important. Liposome behavior is 
closely related to the release of the drugs and is affected 
by many factors. Changes in the fluidity of the membrane 
cause changes in membrane permeability. Because of the 
trans-membrane concentration gradient, the liposome-
encapsulated drug moves by bulk diffusion into the 
cancer cells, forming a higher concentration of the drug 
at the target site, resulting in a strong killing effect on the 
cancer cells. Therefore, the goal of local chemotherapy 
is achieved.
CONCLUSION
We investigated the preparation and characteristics 
of RA-L-G. The diffusion of RA-L-G across the mouse 
skin was also explored. The Qn (%) of RA-L-G was the 
lowest among RA-L-G, RA-L, and RA. The study shed 
light on our understanding of the behavior of RA-L-G. 
Its diffusion across the body barriers depended on the 
characteristics of the barrier, such as the protein quantity 
and types, and the distribution of the polarity. It was 
significant to research thoroughly.
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